-
1
-
-
34248590514
-
The role of vildagliptin in the management of type 2 diabetes mellitus
-
Kleppinger EL, Helms K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother 2007; 41: 824-32.
-
(2007)
Ann Pharmacother
, vol.41
, pp. 824-832
-
-
Kleppinger, E.L.1
Helms, K.2
-
2
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
3
-
-
33846844912
-
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug
-
Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 2007; 9: 153-65.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 153-165
-
-
Idris, I.1
Donnelly, R.2
-
4
-
-
34347393269
-
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
-
He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46: 577-88.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 577-588
-
-
He, Y.L.1
Serra, D.2
Wang, Y.3
Campestrini, J.4
Riviere, G.J.5
Deacon, C.F.6
Holst, J.J.7
Schwartz, S.8
Nielsen, J.C.9
Ligueros-Saylan, M.10
-
5
-
-
84875670059
-
Non-compartmental analysis
-
In:, eds. D'Agostino RB, Sullivan L, Massaro J. Hoboken: Wiley & Sons, dx.doi.org/10.1002/9780471462422.eoct340
-
Bulitta JB, Holford NHG. Non-compartmental analysis. In: Wiley Encyclopedia of Clinical Trials, eds. D'Agostino RB, Sullivan L, Massaro J. Hoboken: Wiley & Sons, 2008; dx.doi.org/10.1002/9780471462422.eoct340
-
(2008)
Wiley Encyclopedia of Clinical Trials
-
-
Bulitta, J.B.1
Holford, N.H.G.2
-
6
-
-
34548324787
-
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
-
He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 787-802
-
-
He, Y.L.1
Sadler, B.M.2
Sabo, R.3
Balez, S.4
Wang, Y.5
Campestrini, J.6
Laurent, A.7
Ligueros-Saylan, M.8
Howard, D.9
-
8
-
-
84863014645
-
-
S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA.
-
Bauer RJ. S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA. 2008.
-
(2008)
-
-
Bauer, R.J.1
-
9
-
-
84863021457
-
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes
-
Landersdorfer CB, He Y-L, Jusko WL. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol 2012; 73: 373-390.
-
(2012)
Br J Clin Pharmacol
, vol.73
, pp. 373-390
-
-
Landersdorfer, C.B.1
He, Y.-L.2
Jusko, W.L.3
-
10
-
-
0027998106
-
Pharmacologic target-mediated drug disposition
-
Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248-52.
-
(1994)
Clin Pharmacol Ther
, vol.56
, pp. 248-252
-
-
Levy, G.1
-
11
-
-
0035730322
-
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
-
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-32.
-
(2001)
J Pharmacokinet Pharmacodyn
, vol.28
, pp. 507-532
-
-
Mager, D.E.1
Jusko, W.J.2
-
12
-
-
61449129605
-
Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs
-
He H, Tran P, Yin H, Smith H, Flood D, Kramp R, Filipeck R, Fischer V, Howard D. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. Drug Metab Dispos 2009; 37: 545-54.
-
(2009)
Drug Metab Dispos
, vol.37
, pp. 545-554
-
-
He, H.1
Tran, P.2
Yin, H.3
Smith, H.4
Flood, D.5
Kramp, R.6
Filipeck, R.7
Fischer, V.8
Howard, D.9
-
13
-
-
33646901012
-
Target-mediated drug disposition and dynamics
-
Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72: 1-10.
-
(2006)
Biochem Pharmacol
, vol.72
, pp. 1-10
-
-
Mager, D.E.1
-
14
-
-
20444406121
-
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile
-
Brandt I, Joossens J, Chen X, Maes MB, Scharpe S, De Meester I, Lambeir AM. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile. Biochem Pharmacol 2005; 70: 134-43.
-
(2005)
Biochem Pharmacol
, vol.70
, pp. 134-143
-
-
Brandt, I.1
Joossens, J.2
Chen, X.3
Maes, M.B.4
Scharpe, S.5
De Meester, I.6
Lambeir, A.M.7
-
15
-
-
0033533402
-
NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV
-
Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999; 38: 11597-603.
-
(1999)
Biochemistry
, vol.38
, pp. 11597-11603
-
-
Hughes, T.E.1
Mone, M.D.2
Russell, M.E.3
Weldon, S.C.4
Villhauer, E.B.5
-
16
-
-
0033619675
-
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
-
Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
-
(1999)
Regul Pept
, vol.85
, pp. 9-24
-
-
Mentlein, R.1
-
17
-
-
61449170189
-
Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
-
He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-44.
-
(2009)
Drug Metab Dispos
, vol.37
, pp. 536-544
-
-
He, H.1
Tran, P.2
Yin, H.3
Smith, H.4
Batard, Y.5
Wang, L.6
Einolf, H.7
Gu, H.8
Mangold, J.B.9
Fischer, V.10
Howard, D.11
-
18
-
-
0037777695
-
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
-
Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-89.
-
(2003)
J Med Chem
, vol.46
, pp. 2774-2789
-
-
Villhauer, E.B.1
Brinkman, J.A.2
Naderi, G.B.3
Burkey, B.F.4
Dunning, B.E.5
Prasad, K.6
Mangold, B.L.7
Russell, M.E.8
Hughes, T.E.9
-
19
-
-
77955809148
-
Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients
-
Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010; 50: 873-85.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 873-885
-
-
Retlich, S.1
Duval, V.2
Graefe-Mody, U.3
Jaehde, U.4
Staab, A.5
-
20
-
-
33947234683
-
Nonlinearity detection: advantages of nonlinear mixed-effects modeling
-
Jonsson EN, Wade JR, Karlsson MO. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2000; 2: E32.
-
(2000)
AAPS PharmSci
, vol.2
-
-
Jonsson, E.N.1
Wade, J.R.2
Karlsson, M.O.3
-
21
-
-
0035216180
-
Ways to fit a PK model with some data below the quantification limit
-
Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
-
(2001)
J Pharmacokinet Pharmacodyn
, vol.28
, pp. 481-504
-
-
Beal, S.L.1
-
22
-
-
34247887681
-
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
-
Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
-
(2007)
AAPS J
, vol.9
-
-
Bauer, R.J.1
Guzy, S.2
Ng, C.3
|